comparemela.com

Latest Breaking News On - Exor ventures - Page 9 : comparemela.com

A former Blackstone exec wants to salvage WeWork from bankruptcy

The company has renegotiated more than 500 of its leases, and is working on doing so with another 400.

Granite creekUnited statesNew yorkNew jerseySofiya gradBritish columbiaFort worthFort smithNorthwest territoriesNew york stock exchangeJoe abramsHahnfeld hoffer stanfordRussell brandJessica mathewsAdam neumannBen weiss

Italian BNPL startup Qomodo raises €34 5m in pre-seed funding

Italian fintech Qomodo has raised €34.5m in a seed funding round led by Fasanara Capital.

Luca ascaniAndrea gennariniGiuseppe lacerenzaGiorgio tinacci casavoSimone mancini scalapayFrancesco filiaMark ransfordBenedetta arese luciniAttilio mazzilliAntonio asseretoPietro invernizziDavide fioranelliGianluca coccoWilliam nealeRaffaele terrone scalapayStiven muccioli

Qomodo Raises €34 5M in Pre-Seed Funding

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!

Andrea gennariniFreddy kellyRaffaele terroneWilliam nealeGianluca coccoMark ransfordChrister hollomanStiven muccioliAttilio mazzilliKai hansenSerge chiaramonteBenedetta arese luciniSimone manciniGiorgio tinacciLuca ascaniPietro invernizzi

PhaseV Raises $15M for ML-Driven Clinical Trial Optimization

PhaseV a pioneer in causal machine learning (ML) technology that optimizes clinical trial design and analysis, announced today that i..

Noam ohanaShould knowViola venturesExor venturesClinical trial designImprove overallManaging director

Advanced tech company, PhaseV, has raised $15 million in funding

Advanced tech company, PhaseV, has raised $15 million in funding that it says it will use to ‘push the boundaries of machine learning for clinical trial optimization’.

Zvika orronMiriam kidronRaviv prylukNoam ohanaOramed pharmaceuticals incViola venturesExor venturesPharmaceuticals incMarkets amp regulationsMachine learningClinical trial

vimarsana © 2020. All Rights Reserved.